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Abstract 
The present study aims at offering empirical evidence to improve existing knowledge and theory building on research 
infrastructure evaluation. Through an inductive case study research strategy, an innovative cost-benefit analysis 
framework has been used to assess the impact of an applied research infrastructure. The case study is the National 
Hadrontherapy Centre for Cancer Treatment (CNAO) located in Pavia (Italy). CNAO is an applied research facility 
specialised in hadrontherapy, an advanced oncological treatment showing clinical advantages as compared to 
traditional radiotherapy, at the same time being more expensive as it exploits non-commercial accelerators 
technology and sophisticated control and dose delivery systems. The analysis shows that with a fairly high probability 
the Centre provides a positive net contribution to society’s welfare. Source of benefits are mainly health treatments to 
patients, for whom gains in terms of longer or better lives are guaranteed as compared to a counterfactual situation 
where they are treated with conventional therapies or they have no alternatives. Such benefits are the direct 
consequences of the application to end users of the knowledge developed in the Centre with research activities and 
are quantified and assessed on the basis of conventional Cost-Benefit Analysis (CBA) approaches for health benefits. 
Additional benefits generated by the Centre are typical of research infrastructures in different scientific domains and 
refer to technological spillovers (namely creation of spin-offs, technological transfer to companies in the supply chain 
and to other similar facilities), knowledge creation (production of scientific outputs), human capital formation 
(training of doctoral students, technicians and professionals in the field of hadrontherapy) and cultural outreach 
(students, researchers and wider public visiting the facilities). Evidences show that the adopted CBA framework is a 
promising avenue as compared to existing alternative methodologies informing decision-making. Further research is 
however needed to fine tune the methodology, in particular for what concerns technological spillovers and knowledge 
creation benefits.  
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1 Introduction 
Research development and innovation (RDI) have definitely been recognised by policy makers as 
fundamental drivers of economic growth (European Commission, 2014a; Krammer, 2015; OECD, 2015; 
Sakurai et al., 1996). Capital – intensive research projects are developing at rapid pace both in number, size 
and cost (ESF, 2013; OECD, 2010a; ESFRI, 2010). These investment projects include both pure research 
infrastructures (RI), carried out for the main purpose of increasing the understanding of fundamental 
scientific principles and producing new ideas, but also applied research facilities aimed at acquiring new 
knowledge directed to a practical purpose (e.g. creating a new compound, technology or product). 
Considering the public budget constraint scenario, there is a growing debate on the opportunity to invest 
huge public sources in such big research program and related infrastructure and on the evaluation approaches 
and evidence based studies available to guide policy decisions (Hallonsten et al., 2004; Salter and Martin, 
2000; Science and Technology Facilities Council, 2010; SQW Consulting, 2008; Vilkkumaa et al, 2015). In 
the past few years, preliminary attempts have been made to provide guidelines and empirical data for 
consultants and public officers involved in appraising RI projects (European Commission, 2014b; JASPERS, 
2013). These attempts try to improve existing methodological frameworks of the Cost-Benefit Analysis 
(CBA), largely adopted in public decision-making to assess investment projects, into the practice of the RDI 
sector. Starting from these works, Florio and Sirtori have explored and discuss the most relevant 
methodological issues involved in a CBA for capital- intensive RDI projects and developed a new CBA 
framework to evaluate the net social benefits of RIs (Florio and Sirtori, 2014). This method appears as the 
more complete and sound yet been developed in the existing literature for RIs evaluation. However, the 
application of this brand new CBA framework in this field of RIs is still limited, so “to what extent the CBA 
can reveal to be useful decision tool in this area is an open question” (Florio and Sirtori, 2014, p. 37). 
The present study attempts to fill this gap testing the RIs’ CBA framework to an applied research 
infrastructure aiming at offering empirical evidence to improve existing knowledge and theory 
building/development on RI evaluation.  
Medical Sciences are a privileged field of applied research infrastructure. Based on Riportal database on RI, 
almost 15% of all the RIs in Europe are of this scientific domain, and within the European Strategy Forum 
on Research Infrastructures roadmap (ESFRI, 2010), medical sciences is the scientific domain with the major 
share of priority projects. 
Medical science and health care sector are consolidate and still growing fields for literature and expertise on 
economic evaluation of new procedures, services and programs (Drummond, 2005; Drummond and 
McGuire, 2001; Neumann, 2005). Studies have been conducted by scholars from different fields such 
economists, medical researchers, clinicians with the aim to compare alternative courses of action in terms of 
both their costs and consequences (Drummond, 2005). Different methods have been developed to perform 
health care economic evaluation, each of those dealing with costs but differing in the way benefits are 
measured and valued. Among those, CBA, which values the benefits in monetary terms, is considered the 
main evaluation method and it is one of the most widespread and known to judge whether an intervention is 
worthwhile (Brent, 2003). Nonetheless, at this time there is scant evidence of CBA systematically performed 
on applied RIs in health care sector.  
The paper adopts an inductive case study research strategy (Yin, 2009). The case study selected (the National 
Hadrontherapy Centre for Cancer Treatment - CNAO - in Pavia, Italy) is a particle accelerator specifically 
designed to provide oncological medical treatment and to carry out research in clinical, radiobiological and 
dosimetric matters. While focusing on the analysis of a specific infrastructure, the paper more generally 
provides useful insights to develop theory on the economic assessment of applied research infrastructure 
through CBA. 
This paper is structured as follows. After a discussion of the main cost and benefit dimensions of Florio and 
Sirtori CBA framework for RI, the research methodology is presented. Then the findings are discussed and 
finally implications and conclusions are presented. 
2 RIs cost-benefit analysis. An evaluation framework 
Cost-Benefit Analysis is an analytical tool aimed at informing decision making on the economic viability of 
projects, programmes, policies or regulatory initiatives by i) identifying all the costs and benefits and ii) 
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measuring them through a monetary value of the welfare change attributable to them (Boardman et al., 2010; 
Florio, 2014). The purpose of CBA is to support a more efficient allocation of resources demonstrating the 
convenience for society of a particular decision against possible alternatives (including the ‘do nothing’ or 
‘business as usual’ alternatives). 
In their recent work Florio and Sirtori (2014) have explored some of the methodological challenges involved 
in a CBA framework for capital-intensive research infrastructure projects. Developing Drèze and Stern’s 
(1987, 1990) CBA theoretical framework, the scholars propose a conceptual model based on the estimation 
of quantities and shadow prices of cost aggregates, and a five main categories of economic benefits:  
1. Knowledge output: this relates to the production and dissemination of new knowledge in a given 
scientific field, and it is typically related to scientific publications;  
2. Technological spillovers: this is related to the transfer of knowledge related to the technological 
development and passed either to companies in the supply chain or to other similar research facilities;  
3. Human capital formation: this relates to the training and educational benefits of students and 
professionals involved in research activities;  
4. Cultural effects of the project outreach activities: in many cases, particularly when dealing with large and 
high-tech infrastructure projects, benefits are generated by activities addressed to the wider public and 
aimed at disseminating scientific knowledge through conferences, events and visits.  
5. Benefits produced by the service provided by the infrastructure to its users: these are typical and often 
the most relevant one of applied research facilities, e.g. effects on the health of treated patients, 
environmental protection services, energy efficiency, testing of materials for private companies and 
license deals, etc.  
 
The conceptual model includes also a non-use (existence) value of scientific discover, which is however less 
relevant in the case of applied research facilities and therefore it will not be considered in the present 
analysis.  
According to this methodological framework, a research infrastructure is assessed to produce net benefits to 
society if the sum of the net present values of the aforementioned categories of benefits outweigh its costs, 
including the use-costs related to the present value of capital, labour cost (including scientific personnel) and 
labour costs of other administrative and technical staff working at the RI, other operating costs, such as 
materials, energy, communication, maintenance, etc., and negative externalities, like air pollution or noise 
during construction and operations.  
3 The research method  
The goal of this paper is to test the soundness and reliability of Florio and Sirtori’s CBA evaluation 
framework for assessing applied research infrastructure, aiming at offering empirical evidence to improve 
existing knowledge and theory development on RI evaluation.  
Case study is a robust research strategy methodology to investigate a contemporary phenomenon in depth 
within a real-life context (Yin, 2009). Given the novel of theoretical contributions in this field, a qualitative 
research methodology based on an inductive single-case study approach was deemed the most appropriate 
method (Edmonson and McManus, 2007; Eisenhardt, 1989; Yin, 2009). Among the RIs in healthcare, the 
National Hadrontherapy Centre for Cancer Treatment (CNAO) in Pavia, Italy, has been selected.  
 
Hadrontherapy 
Hadrontherapy is the field where knowledge and technologies developed by the particle and nuclear physics 
scientific community is used for delivering oncological treatments. Hadrontherapy is a kind of high-precision 
radiotherapy that employs subatomic particles called hadrons. Although, strictly speaking, the term 
“hadrons” can also refer to neutrons, it has become common to restrict the name hadrontherapy to treatments 
that employ positively charged particles, such as protons, helium ions, carbon ions, neon ions and oxygen 
ions. Hadrontherapy was proposed for the first time by the nuclear physicist Robert Wilson in 1946 (Wilson, 
1946) and the first patient was treated at the Lawrence Berkeley Laboratories, California (US), in 1954. The 
pioneering age of hadrontherapy was up to the 90’s: treatments were initially carried out in nuclear physics 
research centers and could rarely rely on adequate imaging, treatment planning, or patient setup technologies. 
In the late 1970s, improvements in accelerator technology, coupled with advances in medical imaging and 
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computing, made proton therapy a viable option for routine medical applications. Nowadays, protons are 
used in 45 facilities, but also the use of Carbon ions is wider spread. The number of dedicated hadrontherapy 
centers is now rapidly increasing. As hadrontherapy is still relative an innovative therapy, there is a growing 
vivid debate about its cost-effectiveness (Lodge et al. 2007, Nakagawa et al. 2009, Lievens et al. 2013, 
Vanderstraeten et al 2014). On one hand, due to still scant evidence available in the past years, some medical 
expert claim against the promotion of a complex treatment modality compare to less-expensive modalities 
(Mills and Schulz 2015, Lodge et al. 2007, Olson et al. 2007). On the other, hadrontherapy centers are 
nowadays providing an increasing amount of clinical evidences, with a growing literature that finds it a very 
promising technology for several cancers treatment (Kamada et al. 2015; 2012, Lukens et al. 2015, Ishikawa 
et al. 2015, Shioyama et al. 2015, Combs et al. 2013a, 2013b, Ramaekers et al. 2013, Schlaff et al. 2014, 
Zips et al. 2013, Rieken et al. 2012, Koto et al. 2014). 
Moreover, Hadrontherapy results more efficacious compare to traditional radiotherapy in reducing collateral 
effects of cancer therapy (Fagundes et al 2015, Torunn et al. 2016). .This promising development has been 
stated also by the ASTRO, American society for Radiation Oncology, (Allen et al. 2012) and the NCI has 
founded research program in this field (Marx V. 2014). 
Finally, thanks to its radiobiological effectiveness hadrontherapy has proven to be the only walkable solution 
for a range of tumor types, i.e. those which are traditionally radio resistant to conventional treatment and 
cancers located very close to vital organs. Similarly, hadrontherapy is the only alternative available for those 
tumors for which radiotherapy was unsuccessful and surgery was not a feasible option. For these reasons it 
has to be not an alternative but a more scientifically advanced clinical solution as compared to radio therapy 
or other conventional treatments.  
 
The CNAO 
The CNAO is an infrastructure comprising two broad distinct areas but functionally integrated: the high 
technology components, made of a set of an accelerator and a set of transport lines of particle beams, and a 
clinical ‘day hospital’ facility, comprising reception desks, waiting and changing rooms. The two areas are 
combined in the three treatment rooms, where the beam lines generated in the facility are used to deliver both 
proton and carbon ion therapy (Rossi, 2011). An experimental beam line with a dedicated room for research 
activities is currently under construction. Research development in the Hadrontheraphy field and the related 
decision to implement the CNAO is closely linked to the fundamental research in the field of Particle and 
Nuclear Physics. In fact the project idea stemmed from the intention to apply the knowledge about hadron 
accelerators developed at Italian Institute for Nuclear Physics (Istituto Nazionale di Fisica Nucleare – INFN) 
and CERN and further oriented for the delivery of cancer treatment by TERA foundation for Hadronterapy 
(Amaldi and Tosi, 1991). The idea was further developed and at CERN with the PIMMS (Proton Ion 
Medical Machine Study) project (Badano et al, 2000) and then finalized by means of a collaboration of 
researchers from CERN, INFN and medical research institutes. The construction of the centre began in the 
summer of 2005 and lasted until 2010.  
 
According to Yin (2009), two main criteria guided the selection of CNAO as case study.  
It is representative of applied research infrastructures in medical field. Specifically, CNAO enables the 
application of knowledge developed in the Particle and Nuclear Physics scientific field to innovative medical 
treatment. The CNAO is a research and health care infrastructure with a double-sided interrelated and 
integrated goal, closely interlinked with each other. On one hand, it aims at treating patients with radio-
resistant and unresectable solid tumours by using hadron particles (either protons or carbon ions) accelerated 
by a synchrotron. On the other hand, the Centre aims at providing Hadrontherapy advanced research in 
clinical, radiobiological and dosimetric matters. Although being in principle two separate activities, clinical 
and research activities are strongly integrated inasmuch as they feed into each other in terms of generating 
and applying research and clinical evidence.  
It is also a critical case study for testing all the dimensions of the Florio and Sirtori’s CBA framework. 
Although hadronterapy is a very promising technology for cancer treatment, (see Fokas et al., 2009; Loeffler 
and Durante, 2013; MacDonald et al., 2012; Tsujii et al., 2014), it is more expensive than conventional 
therapy (it costs approximately EUR 20,000 per patient against EUR 6,000 of conventional therapy) as it 
exploits accelerators technology, sophisticated control and dose delivery systems, highly trained personnel as 
well as large hosting facilities (HIT, 2007). This calls for a serious examination about whether it is worth to 
spend considerable amounts of public money in financing it and, if so, how social benefits can be 
maximised. 
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Data collection  
 
According the need to cover different costs and benefit dimensions, multiple sources of evidence were 
combined using data triangulation (Yin, 2009):  
• Documentary information. A systematic bibliographic review of CNAO project history was 
conducted that included articles in scientific journals, national and local newspapers and healthcare 
magazines. The search was performed using the Italian integrated library database, which provides 
access to the most significant private libraries and to all university and public national libraries. 
Moreover, reports from scientific and medical association has been consulted. 
• Archival records. The research team have accessed to a number of official documentation and 
CNAO archives in order to retrieve data on medical treatment performed and administrative data on 
investment and operational cost, personnel organizational plan and human resources, visits to the RI 
by external visitor, suppliers. These documents and data were collected by mail and through on-site 
visits.  
• A set of in-depth interviews with CNAO staff to understand the nature and technical specifications 
of the activities performed and types of services delivered and with the CNAO Health Director to 
evaluate patient demand and clinical protocols, instrumental to the calculation of benefits for 
patients; 
• Semi-structured interviews with the representatives of six CNAO’s supplier firms and the CEO of 
Detector S.r.l. (a company spin-off of CNAO), which have been identified as potentially benefitting 
of technological spillovers; 
• Scientific publications and paper online repositories. A bibliometric research of articles produced by 
CNAO researchers was conducted in order to estimate the social benefit related to knowledge output. 
The search was performed using INSPIRE, PubMed and Web of Science search engines.  
 
Table 1 Source of evidence breakdown by CBA dimensions 
CBA dimension Source of evidence 
Past investment costs Archival records - Administrative data 
Past operating costs Archival records - Administrative data 
Future investment costs Forecast – Administrative data 
Future operating costs Forecast – Administrative data 
Knowledge output 
Scientific publications and paper online repositories;  
CNAO internal archive  
Technological spillovers Semi-structured interviews  
Human capital formation Archival records and forecast – Administrative and Human Resources data 
Cultural effects 
Archival records – Communication office data 
Travel Planning Websites 
Health benefits 
Bibliographic review of articles in scientific journals; 
in-depth interviews with CNAO Health Director 
Source: Authors  
 
CBA basic assumptions 
In line with the CBA standard framework, the analysis is carried out on the basis of the following 
considerations:  
• the unit of analysis is the CNAO in its totality. The infrastructure taken into account is not only the 
hall hosting the particle accelerators but also the other areas functional to the proper functioning of 
the clinical facility. It also includes the new research line facility and related room. 
• All costs and benefits are estimated in incremental terms against a counterfactual scenario in which 
the CNAO would have not existed (do-nothing option). 
• The analysis starts in 2002 (year 0), after the CNAO Foundation was established by the Italian 
Ministry of Health and the investment officially approved. In particular, 2002 is the first year when 
investment costs occurred.  
5 
 
• The analysis spans up to 2031, considered the end year of the useful life of the CNAO synchrotron. 
Specifically, it has been set according to the criterion that when the extraordinary maintenance of the 
machine became so frequent and expensive that replacing it with a new one is more convenient, the 
machine has arrived at its ending. Also, considerations in terms of advancement in the field of cancer 
care and subsequent possible obsolescence of CNAO methods have been taken into account. As a 
result, a time horizon of 30 years has been considered the most appropriate.  
• The analysis is carried out from the perspective of year 2013, thus it is neither a pure ex-ante nor an 
ex-post evaluation. Instead, it entails both to track historical data and to project future flows of costs 
and benefits. Costs and benefits have been quantified and valued in Euro at 2013 constant prices. 
This implied to bring past nominal cost to 2013 value: to this end, an inflation factor, estimated on 
the basis of annual inflation rates for Italy (IMF, 2013), has been applied to past values 
• A constant 3% Social Discount Rate, in line with the provisions for CBA of major projects adopted 
by the European Commissionfor the programming period 2014-2020, has been applied to capitalise 
past flows and discount future flows. 
• In order to account for the uncertainty related to the necessary forecasting exercise, critical variables 
are treated as stochastic, i.e. expressed in terms of probability distributions functions rather than 
punctual 'best guess' values. 
 
In the following sections baseline and ranges associated to the key quantities associated to costs and benefits 
of CNAO are identified, quantified and monetised. Baseline values refer to the most likely values used in the 
deterministic CBA model. Expected values instead refer to outcome values of the probabilistic analysis, 
implemented through a Monte Carlo simulation. 
4 Results 
4.1 Costs  
The analysis of costs includes past and future investment costs and operating costs valued at shadow prices.  
The investment costs include the capital costs of all the fixed assets (e.g. land, constructions buildings, plant 
and machinery, equipment) and non-fixed assets (e.g. start up and technical costs such as design/planning, 
project management, construction supervision) as well as other costs such as energy, personnel, 
administrative consumable goods costs occurred during the construction phase. These categories of costs 
span form 2002 to 2013, which is the investment period.  
Operating costs include: labour costs for the employes; materials needed for maintenance and repair of 
assets; consumption of raw materials and energy; general management and administration. These categories 
of costs span from 2011 up to 2031. Estimates of future values are based on the observation of historical 
costs and on the consideration of forecasts of future personnel involved and direct costs related to the number 
of patients, as well as a periodical renewal of spare parts for maintenance activities. 
Besides investment and operating costs, replacement expenditures (e.g. short-life machinery and/or 
equipment such as beam sources and detectors) and future investment costs have to be considered, e.g. the 
new treatment room dedicated to research activities (its realization is planned to occur from summer 2014 to 
2017). In addition, a constant activity of upgrading and optimisation of technological instruments is 
undertaken, in line with the at-the-edge nature of the activities carried out in the Centre. 
The total discounted cost considered for the purpose of the CBA of the CNAO amounts to 465.9 million 
EUR over the 2002-2031 period. The total amount includes the decommissioning costs (nearly EUR 4 
million expressed at 2013 constant EUR, discounted), calculated as a share (10%) of the accelerators and 
building total investment costs based on experts’ opinion. 
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Table 2 Investment and operating cost 
 Total CNAO cost 
Non discounted (M EUR) 
Total CNAO cost 
Discounted (M EUR) 
Past investment cost, 2002-2013 159.3 188.8 
Future investment cost, (including research line) 2014-2031 28.6 23.8 
Operating costs (2011-2031) 315.8 248.5 
TOTAL 511.7 465.9 
Source: Authors elaboration based on CNAO data. 2013 constant prices. Note: Total amount includes decommissioning costs 
4.2 Applied research benefits on its users 
4.2.1 Benefit for patients treated at CNAO 
Being CNAO conceived to supply hadrontherapy treatments to persons affected by radio-resistant and 
unresectable solid tumors, the most relevant benefit associated with this infrastructure refers to the health 
improvement on treated patients. Typical health benefits associated to clinical activities are decrease in 
mortality rate and increase in the life expectancy suitably adjusted by the quality of life and this is the case 
also for hadrontheraty treatment (see Fokas et al., 2009; Loeffler and Durante, 2013; MacDonald et al., 2012; 
Tsujii et al., 2014) While these benefits are typical of all health infrastructures performing conventional 
treatments, specificities of CNAO is the inherent capacity to expand the scientific knowledge on the clinical 
benefits of hadrontherapy. In fact, hadrontherapy shows promising applications which are still at the infancy 
phase and need research activities which can be immediately translated into the development of innovative 
clinical protocols optimising the existing treatment services or developing brand new ones.  
Valuing this benefit implies, first, to calculate the total number of patients and the breakdown by the 
different clinical treatments, the health benefits associated to a higher effectiveness and lower toxicity level 
for each category of patients and, finally, the estimation of the economic value of life. Drawing from the 
recent most relevant literature, formula (1) illustrates the authors’ method to evaluate health benefits in the 
specific case of CNAO. In particular, this method refers to the human capital approach which has been 
adopted because of its relatively simple operationalisation and more conservative estimations. Further 
discussion on the existing literature is presented below (see section 'The economic value of life'). 
 
𝐴𝐴 = ∑ ∑ ∑  �𝑁𝑁𝑝𝑝,  𝑖𝑖∗𝐸𝐸𝑝𝑝�∗�𝑋𝑋𝑝𝑝𝑖𝑖∗𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑖𝑖�∗𝑄𝑄𝑝𝑝𝐼𝐼𝑖𝑖𝑃𝑃  𝑝𝑝  (1+3%)𝑡𝑡𝑇𝑇𝑡𝑡         (1) 
 
Where:  
N: number of patients  
𝐸𝐸: share of patients who gain additional years of life compared to the identified counterfactual  
𝑋𝑋: number of life years gained 
VOLY: Value of a Statistical Life Year  
Q: coefficient capturing the increased quality of life 
p (1, ..23): clinical protocol  
𝑖𝑖 (1, ..6): age class  
t (1, …30): year of time horizon 
 
The estimation of each component of the formula is discussed in the following sections.  
 
Patients quantification 
The yearly number of CNAO patients shown in Table 3 has been estimated assuming that during routine 
operation CNAO can treat around 1,000 patients per year and that the Centre will run at full capacity only 
from 2020 onwards. These estimates take into account the country demand forecast for protons and carbon 
ions therapy provided by the Italian Association of Radiation Oncology and the existing and future national 
supply of hadrontherapy treatments1. In addition, the total yearly number of patients under each protocol has 
been split by six age-class using historical data as well as opinions of the CNAO medical staff. 
1A proton centre for ocular melanoma already exists in Catania and a proton centre has been recently opened in Trento. 
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Table 3 Patient data breakdown by years 
Protocol Age-class 2011 2012 2013 2014 … 2020 … 2031 Total 
Protocol 1 
15-25 (20) - 2 1 1 … 1 … 1 26 
26-38 (32) 1 2 1 1 … 2 … 2 33 
39-52 (46) - 9 4 1 … 5 … 5 93 
53-66 (60) - 5 5 3 … 5 … 5 86 
67-80 (74) - 8 5 - … 5 … 5 86 
81-95 (88) - - - - … - … - 0 
Protocol 2 
15-25 (20) - - - - … - … - - 
26-38 (32) - 1 - - … 1 … 1 14 
39-52 (46) 1 1 1 1 … 3 … 3 57 
53-66 (60) - 4 2  … 5 … 5 85 
67-80 (74) 2 5 2 1 … 8 … 8 142 
81-95 (88) - - - - … - … - - 
Protocol n…  … … … … … … … … … 
Total  4 46 134 253 … 1,000 … 1,000 16,735 
  Source: Authors based on AIRO and CNAO data 
 
For the purposes of the analysis, a uniform probability distribution function has been assigned to the variable 
“yearly number of patients”. Specifically, a lower and upper bounds of, respectively, 600 and 1,200 have 
been considered meaning that the variable “yearly number of patients” can assume all values between 600 
and 1,200 with equal probability.   
 
Marginal health improvements  
At the time this analysis was performed, CNAO could treat clinical cases falling under 23 clinical protocols 
authorized by the Ministry of Health and activated by the Centre. Of which 12 uses carbon ions, 9 protons 
and 2 are mixed. Other four protocols are currently awaiting approval. However, for the purposes of our 
analysis only the 23 protocols already approved have been considered. Each protocol is associated to a 
specific treatment addressed to a specific type of tumor in a determined organ. Therefore, treatment 
effectiveness and, in turn, the health improvement is strictly linked to the type of protocols considered. Based 
on interviews with the CNAO Health Director, three types of benefits have been identified and linked to each 
treatment provided at CNAO (See Table 4).  
 
Table 4 Types of benefits 
TYPE DESCRIPTION COMMENT 
TYPE 1 Full recovery of 
patients 
The treated patients gain the same life expectancy of the average healthy 
population 
TYPE 2 Treated patients gain 
some additional year 
of life  
This benefit can also be combined with an effect on the quality of life, 
i.e. the patient can enjoy fewer side effects with respect to the ones 
occurring with a counterfactual treatment during the additional years of 
life gained. 
TYPE 3 Better quality of life 
(i.e. lower level of 
pain and suffering)  
A better quality of life means that the patients can enjoy fewer side 
effects such as vomiting, nausea, fatigue, dermatitis, headaches, during 
the treatment time or the additional years of life gained thanks to the 
therapy. The lower level of side effects is due to the lower toxicity of the 
hadrontherapy treatment with respect to the conventional photon 
treatment. In addition to this, better quality of life is also linked to the 
fact that, compared to more traditional treatments, there is a reduction in 
the length of the therapy, with a reduction of all the related costs. 
Source: Authors based on in-depth interviews to CNAO Health Director. 
Following the indications by the CNAO medical staff, each protocol has been associated with one of the 
mentioned types of benefits. Furthermore, the identification of a counterfactual scenario for each type of 
protocols was necessary in order to quantify the marginal benefit associated to the hadrontherapy treatment, 
in particular for what concerns the number of years gained and for the degree of effectiveness (percentage of 
successful treatment) for each protocol. For the large majority of protocols the counterfactual is the “do-
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nothing” since they refer to patients that have no treatment alternative either because they have been already 
treated with an alternative therapy which actually proved not to be successful or they have radio-resistant 
tumours. In other cases the counterfactual is an alternative treatment depending on the pathology: surgery, 
photon therapy (i.e. conventional radiotherapy), a combination of the two above and chemotherapy. Clearly, 
benefits are maximised when the counterfactual situation is the “do-nothing”, since in those cases the overall 
gain due to the therapy coincides with the marginal gain. Once the counterfactual treatments have been 
identified, the quantification of the marginal benefit arising from each protocol has been calculated as: i) 
marginal percentage of patients who fully recover compared to the counterfactual situation for benefit of 
TYPE 1 (Table 5); ii) marginal percentage of patients who gain some additional years of life thanks to 
hadrontherapy with respect to the counterfactual situation for benefit of TYPE 2 (Table 6); iii) marginal 
percentage of patients who benefit from a marginal increase in the quality of life compared to the 
counterfactual situation for benefit of TYPE 3 (Table 7). This third type of benefit can be incremental with 
respect to the other two types. Actually, a patient can gain the same life expectancy of the average healthy 
population (TYPE 1) or some additional years of life (TYPE 2) and for such number of years gained he/she 
can enjoy fewer side effects compared to the counterfactual scenario. 
The data on the local control and the rate of overall survival at different years after the treatment have been 
collected for each type of protocols/tumours as well as for both the hadrontherapy and the counterfactual 
treatments. As for the quantification of the benefit related to the improvement of the quality of life, a quality 
factor ranging from 0 to 1 and that reflect individuals’ perceptions of the quality of life associated with both 
the hadrontherapy and the counterfactual treatments have been identified when enough data on treatment 
toxicity were available. When possible, the quality factors have been quantified based on the matrix of 
performance status developed by Karnofsky (Karnofsky and Burchenal, 1949). 
In order to take into account the uncertainty related to the effectiveness of treatments, a range of variation 
associated to the marginal percentage of patients who recover compared to the counterfactual arising from 
each protocol has been considered instead of punctual values. In particular, a standard deviation of 10% 
around the modal values presented in the Tables 5-7 has been used in the analysis. 
All the marginal benefits have been thoroughly discussed with the CNAO medical staff. Lacking established 
evidence on the effectiveness of some of the treatments provided at CNAO due to their innovative nature the 
estimation of benefits follows a conservative approach inasmuch as the identification and quantification of 
benefits relies by far on existing medical literature on effectiveness of more traditional therapy, in some 
cases adjusted with ‘best guess’ provided by physicians of CNAO. 
 
Table 5 Marginal benefit of Type 1 by protocols 
# of 
protocol Pathology Clinical alternative 
Marginal percentage of patients 
who fully recover compared to the 
counterfactual situation  
1 Proton radiation therapy for chordomas and 
chondrosarcomas of the skull base No alternative 73% 
2 Proton therapy of spine chordoma and 
chondrosarcoma No alternative 73% 
3 Proton therapy of intracranial meningioma  No alternative 33% 
9 Carbon ion therapy of  adenoid cystic 
carcinoma of salivary glands  Surgery + photon therapy 45% 
10 Carbon ion re-irradiation of recurrent 
pleomorphic adenomas  Surgey 21% 
11 Carbon ion re-irradiation of recurrent rectal 
cancer  No alterative* 45% 
12 Carbon ion radiotherapy for bone and soft 
tissue sarcoma of cervico-cephalic area No alterative* 14% 
13 Carbon ion radiotherapy for bone and soft 
tissue sarcoma of trunk No alterative* 33% 
15 Carbon ion therapy of malignant melanoma 
of the mucous of the upper aerodigestive tract Surgery + photon therapy 30% 
16 Carbon ion therapy for high risk prostate 
cancer Photon therapy 43% 
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19 Carbon ions therapy of primary malignant 
tumors of the liver Photontherapy 36% 
Source: Own elaboration based on interviews with CNAO medical staff. Note: (*) No alterative since the patients considered under 
this CNAO protocol are those who cannot be operated. 
Table 6 Marginal benefit of Type 2 by protocols 
# of 
protocol Pathology Clinical alternative 
Marginal percentage 
of patients who fully 
recover compared to 
the counterfactual  
Number of life 
years gained 
with respect 
to the 
counterfactual  
6 Proton boost for locally advanced 
cervico-cephalic area tumors No alternative for advanced tumours 15% 5 
8 Proton re-irradiation of recurrent 
spine  chordoma and 
chondrosarcoma 
No alterative 43% 3 
14 Carbon ion therapy of recurrent 
cervico-cephalic area tumors No alterative* 68% 0.5 
18 Carbon ion therapy for pancreatic 
cancers Palliative chemotherapy 40% 2 
20 Carbon ion re-irradiation of 
recurrent spinal chordoma and 
chondrosarcoma 
No alterative 43% 3 
22 Protons and/or carbon ion integrated 
radiotherapy for poor prognosis in 
patients with operable 
sinonasaltumor 
Surgey + photon therapy 10% 5 
23 Protons and/or carbon ion integrated 
radiotherapy for poor prognosis in 
patients with inoperable 
sinonasaltumor 
Photontherapy* 35% 5 
Source: Own elaboration based on interviews with CNAO medical staff. Note: (*) No alterative since the patients considered under 
this CNAO protocol are those who cannot be operated. 
Table 7 Marginal benefit of Type 3 by protocols 
# of 
protocol Pathology Clinical alternative 
Marginal percentage of 
patients who fully 
recover compared to the 
counterfactual  
Number of life years 
gained with respect to 
the counterfactual  
Quality of life 
adjustment 
factor* 
7 Proton therapy of 
glioblastoma No alterative 100% 1 
0.3 
21 Proton therapy of 
eye melanoma Surgey 100% 15 
0.3 
Note: Protocols 4, 5 and 17 fall under this category. However, due to lack of evidence on marginal benefits compared to the 
counterfactual scenario, they have not been taken into account for precautionary reasons. 
Source: Own elaboration based on interviews with CNAO medical staff.  
 
The economic value of life 
Regardless from the particles used, which in turn means different level of experimentation and proved 
effectiveness, health benefits associated to clinical activities are decrease in mortality rate and increase in the 
life expectancy suitably adjusted by the quality of life. There is a vast and well-established literature on the 
economic value of statistical life (e.g. Abelson, 2008 and 2010; Landefeld and Seskin, 1982; Sund, 2010; 
Viscusi and Aldy, 2003). Following the literature, the monetisation of an increase in the life expectancy 
encompasses the estimation of the Value of Statistical Life (VOSL) and the related Value of a Life Year 
(VOLY). The former is defined as the value that society deems economically efficient to spend on avoiding 
the death of an undefined individual (Sund, 2010). The latter represents, instead, a constant value to be 
attributed to each life year lost due to premature death. The VOLY and the VOSL are related as follows: 
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𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 =  ∑  𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 ∗ (1 + 𝑟𝑟)𝑇𝑇−𝑎𝑎𝑡𝑡=1           (2) 
Where a is the age of the individual or group considered, T is the life expectancy and 𝑟𝑟 is an appropriate 
discount rate. However, in the absence of direct empirical estimates of the VOLY, it is usually derived from 
the VOLS calculated as a discounted stream of annual life year values over the remaining lifetime of the 
subject, adjusted by the survival probabilities (European Commission, 1999).  
Different methods of measuring or approximating society’s willingness to pay for reducing the risk of death 
exist, ranging from contingent valuation survey to benefit transfer, from cost of illness to human capital 
approach (see, for instance, Ashenfelter, 2006; OECD, 2010b, 2012; Sund, 2010; Viscusi and Aldy, 2003).  
 
In this study, the human capital approach has been adopted because of its relatively simple operationalisation 
and more conservative estimations compared to either revealed or stated preference approaches. The human 
capital approach, which has a long history dating back the mid-1960s, assumes that the value to society of an 
individual’s life can be measured as the present discounted sum of the individual’s expected labour earnings 
(Landefeld and Seskin, 1982). The VOSL is calculated based on the lost production in terms of average 
annual wage due to a premature death of an individual. Specifically the following formula applies: 
 VOSL = Σ𝑖𝑖=1,𝑇𝑇−𝑡𝑡(𝑝𝑝𝑡𝑡+1 𝑉𝑉𝑡𝑡+1)/(1 + 𝑟𝑟)𝑖𝑖           (3) 
 
where Σ𝑖𝑖=1,𝑇𝑇−𝑡𝑡  denotes the sum over time from time 𝑡𝑡 (the current age of the individual at risk), 𝑇𝑇 is the age 
at which the individual is expected to die, 𝑝𝑝𝑡𝑡+1  is the probability of the individual surviving from age t to 
age t+i, 𝑉𝑉is the per capita average annual wage, and 𝑟𝑟 is the discount rate.  
 
Although accepted as a rule of thumb, this approach presents some shortcomings. It focuses only on the 
active working population and ignores the value of life of individuals which are excluded from the labor 
market. In order to mitigate such limit a slightly different approach to the standard human capital method has 
been applied. In particular, we have adapted the above formula of VOSL (3) considering per capita GDP 
instead of average annual salary as a measure for the lost production due to a premature death of an 
individual. Since per capita GDP is a measure of gross domestic output attributable to each individual within 
a country, it can be considered a proxy of individual production value (see Jongejan et al., 2005 and Vrijling 
et al., 1998). 
 
Based on the above adapted formula, a VOSL value for each of the six classes of age used for patient 
quantification has been calculated. This is the sum of discounted value of average per capita GDP each 
individual is expected to be endowed with until patient death (82 years). Then, the related VOLY value for 
each age class has been derived using formula (2). The average estimated values of VOLS and derived 
VOLY values are presented in Table 8.  
 
Table 8 Value of VOSL and VOLY for the six classes of age (EUR, 2013 constant price) 
VOSL Class Value of VOSL VOLY 
VOSL (20) 1,156,067 26,036 
VOSL (32) 972,568 25,568 
VOSL (46) 734,126 24,934 
VOSL (60) 467,450 24,117 
VOSL (74) 172,048 22,614 
VOSL (81) 21,567 21,811 
Source: Authors - social discount rate specifically calculated for Italy 
 
Due to the level of criticality of VOSL values within the frame of our analysis, a benchmarking exercise with 
existing values retrieved from the literature and estimated following alternative approaches has been 
performed to set the boundaries of the triangular probability function assigned to the VOSL. Specifically, a 
triangular probability distribution function with lower bound of EUR 1,030 thousand, a modal value of EUR 
1,160 thousand and an upper value of EUR 1,800 thousand has been considered.  
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Having established the range of variation of the three input variables (i.e. number of patients, marginal health 
improvement and economic value of a year of life saved), the total expected present value of the applied 
research benefit on CNAO’s patients amounts to nearly EUR 2 billion, with ranges of possible values 
between nearly EUR 0.9 and 4.1 billion. Although with a large variation, health benefits are quite significant 
and even their estimated minimum value already pay off the total discounted costs.  
4.2.2 Benefit for users of experimental beam line 
A high or medium energy experimental beam line is strongly demanded by researchers in different fields: 
from radiobiology, dosimetry, accelerator physics, beam monitoring and diagnostics, clinical and 
translational research, up to bioengineering and industrial applications (e.g. radiation hardness studies, space 
radiation research, development and material characterization). At present, the priority in the use of the beam 
line of the CNAO has been to clinical treatments; for research experimentsis it has been limited during the 
weekend and night. Therefore, the forthcoming beam line dedicated to experimental research will represent a 
steady service offered by CNAO to third users. An ad hoc survey carried out by CNAO before starting the 
construction of the beam line dedicated to research activities identified around 20 institutions manifesting 
their interest in using it. External users will pay a fee for the use of the beam, which has been estimated 
prudentially by CNAO as triangular distribution ranging from 2,000 to 3,000 EUR/hour with a mode of 
2,500 EUR/hour. These figures have been estimated as the costs incurred by the facility to make the beam 
line available, so it is considered to be a good proxy of the long run marginal cost of the service. Considering 
a use of the beam of 8 hours a day for a number of days ranging from 200 to 225 per year after 2017, the 
expected present value of the benefit spilling-over from the use of the research beam is nearly EUR 45 
million.  
4.3 Value of knowledge outputs 
According to Florio and Sirtori (2014), the total value of knowledge is not only made by the social value of 
producing new information per se but it also comprises the social value attributed to the degree of influence 
of that piece of knowledge on the scientific community. In Florio and Sirtori, the former is captured by the 
number of papers written and valued through the marginal production cost, the latter is reflected in the 
number of people that would cite the paper and valued through the opportunity cost of time employed by a 
scientists to read and understand someone else’s paper and decide to cite it. They propose to use bibliometric 
techniques to measure RI’s scientific output, quantifying the knowledge outputs generated by the “insiders” 
scientists (taken as level 0), papers written by other scientists and citing those of the insiders (level 1), other 
papers citing level 1 papers, and so on. Particle therapy scientific community is relatively ‘small’ and rather 
young, therefore dedicated publications channels are still under development or relatively new, with limited 
coverage by reference database. For this reason, scientific output L0 has been retrieved through a 
combination of records extracted directly from the INSPIRE, PubMed, Web of Science websites and 
unpublished outputs such as conference proceedings made available by CNAO internal archive as well as 
founded in particle therapy thematic websites. To establish future projections of the first level papers (L0) it 
was adopted a non-linear model which assumes a peak in the number of papers in 6 years when the CNAO 
exits from the initial experimental phase, i.e. 2020. This assumption is consistent with the fact that the 
overall survival of patients treated with hadrontherapy, as well as other cancer therapy methods, is usually 
checked 5 years after the treatment to assess the overall effectiveness. According to a prudent approach, no 
other peaks are expected. Projections of L1 have been estimated by assuming an average number of citations 
to papers L0. Specifically, a citation factor with a normal probability distribution with a standard deviation of 
0.3 around the mean values of 1 and 2 has been used, respectively, until and after 2013 according to the 
average number of citations recorded for papers so far produced by CNAO scientists and collaborators, 
assuming that future papers L0 will be on average cited twice than those produced during the construction 
and the experimental phase.  
According to Florio and Sirtori (2014), the average scientist’s hourly compensation is considered a 
reasonable proxy of the marginal production cost of a paper. By analogy, the shadow price of citation is 
estimated using the opportunity cost of time employed by a scientist to read, understand someone else’s 
paper and decide to cite it. Average gross wages were retrieved from Istat database and confronted with 
historical salaries paid by CNAO. Shadow wage has been assumed equal to market wage since the reference 
labour market is assumed to be open to international competition with easy mobility across countries. The 
share of time devoted to research is assumed to follow a triangular distribution with a modal value of 30% 
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for CNAO insider scientists and 80% for extra-CNAO scientists. Similarly, it is assumed that the average 
number of outputs takes a normal distribution with a standard deviation of 0.3 around the mean value of 2 
papers for CNAO insider scientists and of 5 papers for extra-CNAO scientists. These differences between 
CNAO insiders and extra-CNAO scientists are mainly due to the fact that CNAO staff is primarily devoted 
to clinical activities as compared to extra-CNAO staff. As for the average number of reference contained in a 
paper, a review of existing papers in the particle therapy field shows that the number of references is 
generally around 30. In the analysis, therefore it is assumed a normal probability distribution with a standard 
deviation of 0.5 around the mean value of 30. Under these assumptions, the unit production cost/value of L0 
and L1 papers is estimated to be approximately 275 and 265 EUR, respectively. Conversely, following a 
prudential approach, the production value of paper L2 and of those of the subsequent levels have not been 
estimated. As for citations, assuming one hour as the average time needed to decide to cite a paper, the 
average hourly gross salary of scientists is taken as an estimate of the social value of one citation.. 
 
The expected present value of the knowledge output amount to nearly EUR 12.3 million, with ranges of 
possible values between EUR 6.3 and 27 million.  
4.4 Technological spillovers 
According to Florio and Sirtori (2014) model, technological spillovers involve the RI itself, e.g. through 
patents or spinoffs aiming at commercialize RI research breakthroughs, or technological externalities 
produced on the RI’s supply chain. Moreover, they identified other RI’s technological spill overs, derived as 
side effect of on-the-job working and learning by-doing process, remaining very often hidden and difficult to 
be estimated in monetary terms.  
4.4.1 Technological externalities on the RI’s supply chain 
Florio and Sirtori (2014) propose to use the change of net output (i.e. incremental profit) directly imputable 
to the spill over effect, at shadow prices, to value technological externalities on the RI’s supply chain. At this 
purpose, jointly with CNAO administrative office, the suppliers potentially beneficiaries of a sort of 
technological and knowledge transfer have been identified. Their products/service provisioning satisfies very 
specific technical requirements, duly customized to be fitting for the CNAO purpose. On the basis of data 
collected through semi-structured interviews to those selected suppliers, the average incremental profit can 
be approximated by a triangular probability distribution ranging from 1% to 10% with a modal value of 7%. 
The knowledge and technological skills derived by the collaboration with CNAO proved to be particularly 
useful and appealing for the market, due to the fact that CNAO was one of the first hadrontherapy centre 
developed in Europe and recognised as the frontiers in that scientific field. In a number of cases, working for 
CNAO had a labelling effect and eventually lead to opening new markets, increase turnover and 
employment. A benchmark analysis of the average EBITDA margin associated to the considered companies, 
carried out using data gathered from the ORBIS database of world companies’ balance sheets, confirms that 
a baseline value of 7% is reliable. 
The total volume of CNAO external procurement associated with the selected firms amounts to 25.2 million 
EUR (2013 constant prices). Adopting an average utility/sales ratio (increase turnover) with a uniform 
probability distribution ranging from 2 to 4, as derived by literature (Bianchi-Streit et al., 1984; Salina, 2006; 
Schmied, 1975), and considering the above mentioned average incremental profit margin, the suppliers' 
incremental benefit related to technological spill over is obtained. The discounted sum of benefit amounts to 
6.5 million EUR in the baseline case.  
4.4.2 Spin-off 
An additional innovation outcome related to CNAO is the 2009 creation of a spinoff (De.Tec.Tor. S.r.l) 
aimed at commercialising the facility’s research breakthroughs. It is a small company that designs, 
customizes and manufactures high precision particle detectors for on-line beam monitoring and daily quality 
assurance in advanced radiation therapy. According to Florio and Sirtori (2014), the economic value of a 
spin-off should be valued as the expected shadow profit gained by the enterprise during its lifetime, as 
compared to the counterfactual situation. Since the activity of the spin-off will progressively detach from the 
technology endowment gained during the collaboration with CNAO, the time period for which the profits 
gained are considered in the CBA is 11 years. We considered yearly profits recorded from 2010 to 2014, 
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profits estimated by the company for 2015 and a share of the profit estimated for 2015 for 2016 to 2020. The 
discounted sum of benefit amounts to nearly 1 million EUR in the baseline case. 
4.4.3 Other technological spill overs  
The research carried out in the Centre is highly collaborative in nature: since the beginning, research activity 
at CNAO has benefitted from an intense collaboration in particular with INFN and CERN, which led to 
development of shared technological knowledge. Thanks to this collaboration, new expertise and knowledge 
have been developed involving not only technological development, but also a demanding clinical trial and 
experimental phase. This cumulative knowledge is a side-effect of on-the-job working and learning by-doing 
process not protected through intellectual property rights. This makes it difficult to attribute to CNAO a 
specific effect of such technological transfer observed in the scientific or industrial community. An 
experimental proxy to evaluate such category could be the transfer of this knowledge through specific 
contracts to similar centres, thus avoiding costs to undertake own tests and experimentations during the 
design and construction phase. A number of delegations from other centres have been visiting CNAO to 
collect information relevant for their activities. Among them, the MedAustron centre (Austria) purchased 
from CNAO the engineering design at a cost of approximately 8 million EUR. According to estimates made 
by CNAO managers, thanks to the purchased knowledge, MedAustron has benefitted a cost saving of 
approximately 14 million EUR due to avoided costs to develop design studies from scratch and to time 
savings to perform test and experimentations. This value can be considered a direct technological spill over 
benefit of CNAO. However, in order to take into account the uncertainty associated to this value mainly due 
to the difficulties of estimating the share of cost saving strictly ascribable to CNAO, without including those 
ascribable to INFN and CERN, which collaborated in the project design, a triangular probability distribution 
with a minimum value of 10.8 million, a maximum value of 18 million and a mode of 14 million has been 
used in the analysis.  
 
In total, the expected present value of CNAO technological spillovers over the 2001-2031 period amount to 
nearly 22.6 million EUR, of which more than a half (55%) are from avoided costs enjoyed by other 
hadrontherapy centres, 28% corresponding to the benefit on the supply chain and 17% related to the spin-off. 
4.5 Human capital formation 
According to Florio and Sirtori (2014), and following the standard CBA framework for education 
programmes, the present value of human capital accumulation benefits produced by the research 
infrastructure can then be defined as the sum of the increasing earnings, gained by RI’s students and former 
employees, since the moment they leave the project. At CNAO, the human capital formation benefit is 
expected for students and young workers, such as: i) University Students, staying at CNAO for 
approximately 9 month during their master degree or first level master and working on CNAO-related 
activities for their thesis; ii) Researchers, remaining at CNAO up to 1 year, and who could be distinguished 
among fellows and doctoral students; iii) Interns, staying at CNAO for approximately 5 months for a stage, a 
training course or a specialization course; iv) Technical Medical Radiology Volunteers, remaining at CNAO 
for 3 months.  
The number of persons belonging to the four mentioned categories arriving every year at CNAO has been 
retrieved from CNAO Personnel Statistics reports, available until 2013. For the period 2014-2031, the 
number of incoming university students/researchers/interns/volunteers has been stated with a normal 
distribution with standard deviation of 0.3 around the mean represented by 2013 value. The total number is 
507. 
The estimation of the benefit implies tracking careers of cohorts of students in the long run and matching 
data on careers and estimating the percentage increase in their salary thanks to the experience at CNAO. 
Based on interviews to CNAO management and Human Resource office, the professional sectors where 
CNAO former students/young researchers are expected to find a job have been identified (i.e. other 
hadrontherapy facilities, research centres, academia, hospital, industry, and other sectors). Additionally, the 
share of students who find a job in one of the six mentioned sectors has been hypothesised. 
The average salary for each of these professions, at four different career levels, has been retrieved from Istat 
databases. Using a logarithmic function, a continuous salary curve has been estimated for each professional 
sector and the average incremental salary by year of career has been calculated. 
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Concerning the incremental annual salary earned by former CNAO students/researchers, with a benefit 
transfer approach based on a LHC case study by Florio et al., (2015) it has been estimated that the salary 
bonus for having spent a training period at the CNAO can range from 1% to 10% with a triangle probability 
distribution with mode value of 5%. Based on this range of variation and making the following two 
assumptions: i) CNAO students/researchers enter the labour market immediately after their experience at the 
CNAO; and ii) the incremental salary benefit is spread over their entire work career, lasting 40 years, the 
expected present value of the benefit for human capital formation is nearly EUR 15.4 million. 
4.6 Outreach and cultural impact 
Many research infrastructures organize outreach events and services aimed at informing the public on 
advances in science and technology. Florio and Sirtori (2014) suggest exploiting the CBA approaches to 
evaluate cultural tourism for scientific tourism as well estimating the willingness to pay of the general public 
for visiting the RI through the travel cost method. It consists in evaluating a good through the full travel cost 
incurred in its consumption, including the cost of trips (fuel, train or airplane ticket, etc.), the opportunity 
cost of time spent in travelling, the cost of accommodation, food, and so on. Given the number of visitors to 
the site in a given time period and the marginal economic cost of a trip, the demand curve can be derived and 
the willingness to pay for a visit estimated.  
Since 2011, CNAO has organized free guided tours for students from high schools, universities, research 
institutes and scientific organizations, as well for general public. The number of visitors has been quantified 
taking into account the visitors for the period 2011-2014 and a maximum number of 1,800 visitors per year 
from 2014 onwards, considering capacity constraints.  
Thanks to historical data of visits, five possible travel areas of origin and five different transport modes has 
been identified and an average travel cost (including lunches/accommodation, trip and the opportunity cost 
of time spent in travelling) has been estimated for each combination. The average cost and travel time has 
been retrieved from different travel websites. Almost 97% of visitors are supposed to remain for one day 
only, with a cost ranging from 8 to 12 EUR. The remaining nearly 3% of visitors are assumed to stay one 
night with a total cost ranging from 100 to 140 EUR per person. Based on the HEATCO travel time values 
related to working or leisure trips (HEATCO, 2002), the opportunity cost of time for different categories of 
visitors has been estimated. In the risk analysis, it was assumed that these values take a normal probability 
distribution with a standard deviation of 0.3 with respect to the mean values. 
 
The total expected present value of the cultural outreach amounts to nearly EUR 6.2 million with ranges of 
possible values between nearly EUR 2.4 and 9.6 million. 
4.7 The CNAO expected net present value 
The results of the analysis, summarized in Table 9, show that over a time horizon of 30 years and under a 
number of rather conservative assumptions on forecasts, the RI is expected to provide net benefits amounting 
to approximately 1.6 billion discounted EUR (with a standard deviation of approximately 500 MEUR). In 
addition, risk analysis performed with the Monte Carlo simulation techniques  (see results in Figure 1) shows 
that the project is affected by a low level of risk, considering that there is nil probability for the net present 
value to be negative.  
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Table 9 Baseline and expected values  
Asset 
Non 
discounted 
baseline value 
(Million Euro) 
Discounted 
baseline 
value 
(Million 
Euro) 
Share of 
total 
Expected 
discounted 
value 
(Million Euro) 
Standard 
deviation 
TOTAL PAST INVESTMENT 
COSTS (2002-2013) 
159.3 188.8 41% - - 
TOTAL OPERATING COSTS 
(2002-2031) 315.8 248.5 53% 
- - 
TOTAL FUTURE INVESTMENT 
COSTS (2014-2031) 28.6 23.8 5% 
- - 
DECOMMISSIONING COST 8.0 4.7 1% - - 
TOTAL COSTS 511.7 465.9 100% - - 
HEALTH BENEFITS FOR 
PATIENTS 2,606.3 1,958.1 95.10% 2,028.6 495.7 
BENEFIT FOR USERS OF THE 
EXPERIMENTAL BEAM 63.0 45.2 2.20% 45.1 3.7 
KNOWLEDGE OUTPUT 14.9 11.7 0.57% 12.1 2.5 
TECHNOLOGICAL 
EXTERNALITIES ON SUPPLY 
CHAIN 
5.4 6.5 
1.08% 22.6 2.0 SPIN-OFF 1.1 0.9 
OTHER TECHNOLOGICAL 
SPILLOVERS 14.5 14.9 
HUMAN CAPITAL FORMATION 35.6 15.4 0.75% 15.4 7.4 
OUTREACH AND CULTURAL 
IMPACT 8.0 6.1 0.30% 6.2 0.9 
TOTAL BENEFITS 2,748.6 2,058.9 100% 2,130.0 - 
Source: Authors elaboration based on CNAO data. 2013 constant prices. 
 
Figure 1 Economic Expected Net Present Value  
  
Source: Authors 
5 Conclusion 
The paper aims at testing the pioneering Florio and Sirtori’s CBA framework for the assessment of the net 
socio-economic impact of an applied research facility thus contributing to the scientific knowledge and 
theory in evaluating research infrastructure. In order to meet this goal an inductive case study was selected 
among applied research infrastructure in the healthcare sector.  
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The framework provides useful insights to measure benefits related to applied research infrastructure and to 
assess the relation between advancement in scientific knowledge and the materialisation of social benefits for 
users.  
Overall the analysis shows that the CBA proved to be a promising tool for the provision of a systematic 
information basis to support decision making. In particular, it allows for clearly identifying and as far as 
possible quantifying and translating into economic values aspects of the activities of applied scientific 
research which do not usually undergo an in-depth economic scrutiny. 
Empirical testing shows that the composition of benefits of an applied RI is heavily affected by the category 
of benefits relating to the services provided by the infrastructure to its users. Particularly, the magnitude of 
the benefits produced to its patients is by far greater than any other benefit category. Indeed, CNAO is an 
health care applied RI and clinical treatments provided are the main application of knowledge and 
technologies developed by the nuclear and particle physics scientific community as well as of the advanced 
research activities which is continuously carried out in the Centre. Such positive results are mainly explained 
by the fact that the assumptions made for the estimation of applied research benefits on patients are 
underpinned by a strong and well accepted scientific case about the effectiveness of hadrontherapy for tumor 
treatment. It is therefore not surprising that most of the benefits are coming from the health improvements of 
patients due to the provision of hadrontherapy treatments, which qualifies as the direct application of 
research results to external users of the facility. The analysis confirmed that benefits are maximised as much 
as the selection of patients is made considering the marginal effect of the therapy provided in CNAO as 
compared to conventional treatment. The results point to a strong economic case to support CNAO 
considering the significant contribution to satisfy an increasing demand of tumor clinical treatment for 
specific categories of patients. Even under conservative estimation, benefits for patients from the 
hadrontherapy alone would overweight the total net present value of costs and therefore provide alone a 
proper justification for CNAO.  
At the same time, the test of the methodological framework proved to be challenging for the well-known 
issue of data intensity of the analytical tool and, even more, for the specificities of the research activities 
carried out in the Centre. Some further research is needed in order to better capture the nature and magnitude 
of some of the core activities of these kinds of facilities; in particular as far as knowledge creation and 
technological transfer are concerned. There is in fact the impression that such benefits are underestimated in 
the results presented here, for a number of reasons which are however related to the specific nature of 
research activities carried out in the Centre.  
First of all, the scientific knowledge developed in the Centre is only partially and unsystematically translated 
into tangible outputs suitable to be tracked with scientometric techniques. Opinions collected on field support 
the argument that there is an intensive informal exchange of knowledge in the field of particle therapy which 
is not reflected in refereed journal article but are mainly transmitted with participation in conferences and 
events, working groups and even bilateral meetings and visits. This is exacerbated by the rather hybrid 
character of the scientific communities involved in particle physics which range from Nuclear and Particle 
Physics to Accelerator technologies to Health and medical treatment with extensive cross-fertilisation among 
them. The accumulation of knowledge in such a small but heterogeneous community is a collaborative effort 
which makes it is difficult to attribute to a specific research programme or facility and it not ruled by strict 
intellectual property rights 
The same argument applies to some extent also to the aspect of technological spillover and transfer. As 
mentioned above, the research carried out in the Centre is highly collaborative in nature, which led to 
development of shared knowledge and makes it difficult to attribute to the construction or operation of 
CNAO a specific effect of technological transfer observed in the scientific or industrial community. 
Moreover, interactions with industrial actors or other medical centres interested in developing the 
technological capacities developed thanks to the construction and operation of CNAO are normally managed 
in an informal and relatively open and collaborative way, as it is typical in the scientific field. While this may 
result in a more effective and successful way of producing and spreading the knowledge within the scientific 
community, it makes it more challenging to assess the marginal increase in the technological development in 
the community attributable to the specific research facility. Within CNAO there is an increasing awareness 
that much of the knowledge and competences developed by either the scientific and technical staff internal to 
CNAO but also by external users and the wider network is huge and not sufficiently exploited. It is currently 
under discussion the possibility for CNAO to set up a dedicated structure to sell on the market the design, 
planning and experimental capacity in the hadrontherapy field developed with the construction of CNAO. If 
this strategy should materialise, the potential economic and financial benefit of such an operation are 
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expected to be significant and would partly reflect the benefits which currently could not be fully captured by 
the analysis.  
To sum up, the CBA framework proved to be a suitable and relevant framework of analysis, useful for the 
assessment of the infrastructure of applied research. At the same time further research would be necessary to 
fine tune and expand the current methodologies and techniques to track the creation and dissemination of 
scientific and technological knowledge within a given scientific community attributable to a specific research 
facility.   
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